Literature DB >> 34540133

Statistical models for composite endpoints of death and non-fatal events: a review.

Lu Mao1, KyungMann Kim1.   

Abstract

The proper analysis of composite endpoints consisting of both death and non-fatal events is an intriguing and sometimes contentious topic. The current practice of analyzing time to the first event often draws criticisms for ignoring the unequal importance between component events and for leaving recurrent-event data unused. Novel methods that address these limitations have recently been proposed. To compare the novel versus traditional approaches, we review three typical models for composite endpoints based on time to the first event, composite event process, and pairwise hierarchical comparisons. The pros and cons of these models are discussed with reference to the relevant regulatory guidelines, such as the recently released ICH-E9(R1) Addendum "Estimands and Sensitivity Analysis in Clinical Trials". We also discuss the impact of censoring when the model assumptions are violated and explore sensitivity analysis strategies. Simulation studies are conducted to assess the performance of the reviewed methods under different settings. As demonstration, we use publicly available R-packages to analyze real data from a major cardiovascular trial.

Entities:  

Keywords:  Clinical trials; Estimand; Recurrent event; Semi-competing risks; Time to first event; Win ratio

Year:  2021        PMID: 34540133      PMCID: PMC8442983          DOI: 10.1080/19466315.2021.1927824

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.586


  36 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Authors:  Nick Freemantle; Melanie Calvert; John Wood; Joanne Eastaugh; Carl Griffin
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

3.  Shared frailty models for recurrent events and a terminal event.

Authors:  Lei Liu; Robert A Wolfe; Xuelin Huang
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

4.  Semiparametric regression for the weighted composite endpoint of recurrent and terminal events.

Authors:  Lu Mao; D Y Lin
Journal:  Biostatistics       Date:  2015-12-14       Impact factor: 5.899

5.  Graphing the Win Ratio and its components over time.

Authors:  Dianne M Finkelstein; David A Schoenfeld
Journal:  Stat Med       Date:  2018-09-11       Impact factor: 2.373

6.  Analysis of ordered composite endpoints.

Authors:  Dean Follmann; Michael P Fay; Toshimitsu Hamasaki; Scott Evans
Journal:  Stat Med       Date:  2019-12-19       Impact factor: 2.373

7.  Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?

Authors:  Stefan D Anker; John J V McMurray
Journal:  Eur Heart J       Date:  2012-08-27       Impact factor: 29.983

8.  Weighted win loss approach for analyzing prioritized outcomes.

Authors:  Xiaodong Luo; Junshan Qiu; Steven Bai; Hong Tian
Journal:  Stat Med       Date:  2017-03-26       Impact factor: 2.373

9.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615

10.  Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.

Authors:  Jean-François Timsit; Marlieke E A de Kraker; Harriet Sommer; Emmanuel Weiss; Esther Bettiol; Martin Wolkewitz; Stavros Nikolakopoulos; David Wilson; Stephan Harbarth
Journal:  Intensive Care Med       Date:  2017-05-02       Impact factor: 17.440

View more
  2 in total

1.  On recurrent-event win ratio.

Authors:  Lu Mao; KyungMann Kim; Yi Li
Journal:  Stat Methods Med Res       Date:  2022-03-29       Impact factor: 2.494

2.  On restricted mean time in favor of treatment.

Authors:  Lu Mao
Journal:  Biometrics       Date:  2021-09-25       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.